Lipitoids, which self-assemble with DNA and RNA, can serve as cellular delivery systems for antiviral therapies that could prevent COVID-19 and other coronavirus infections. (Illustration courtesy of R.N. Zuckermann)
Cellular delivery system developed at Berkeley Lab’s Molecular Foundry could be missing link in battle against SARS-CoV-2
A team of scientists from Stanford University is working with researchers at the Molecular Foundry, a nanoscience user facility located at the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab), to develop a gene-targeting, antiviral agent against COVID-19.
Last year, Stanley Qi, an assistant professor in the departments of bioengineering, and chemical and systems biology at Stanford University and his team had begun working on a technique called PAC-MAN – or Prophylactic Antiviral CRISPR in human cells – that uses the gene-editing tool CRISPR to fight influenza.
But that all changed in January, when news of the COVID-19 pandemic emerged. Qi and his team were suddenly confronted with a mysterious new virus for which no one had a clear solution. “So we thought, ‘Why don’t we try using our PAC-MAN technology to fight it?’” said Qi.
Since late March, Qi and his team have been collaborating with a group led by Michael Connolly, a principal scientific engineering associate in the Biological Nanostructures Facility at Berkeley Lab’s Molecular Foundry, to develop a system that delivers PAC-MAN into the cells of a patient.
Like all CRISPR systems, PAC-MAN is composed of an enzyme – in this case, the virus-killing enzyme Cas13 – and a strand of guide RNA, which commands Cas13 to destroy specific nucleotide sequences in the coronavirus’s genome. By scrambling the virus’s genetic code, PAC-MAN could neutralize the coronavirus and stop it from replicating inside cells.
It’s all in the delivery
Qi said that the key challenge to translating PAC-MAN from a molecular tool into an anti-COVID-19 therapy is finding an effective way to deliver it into lung cells. When SARS-CoV-2, the coronavirus that causes COVID-19, invades the lungs, the air sacs in an infected person can become inflamed and fill with fluid, hijacking a patient’s ability to breathe.
“But my lab doesn’t work on delivery methods,” he said. So on March 14, they published a preprint of their paper, and even tweeted, in the hopes of catching the eye of a potential collaborator with expertise in cellular delivery techniques.
Soon after, they learned of Connolly’s work on synthetic molecules called lipitoids at the Molecular Foundry.
Lipitoids are a type of synthetic peptide mimic known as a “peptoid” first discovered 20 years ago by Connolly’s mentor Ron Zuckermann. In the decades since, Connolly and Zuckermann have worked to develop peptoid delivery molecules such as lipitoids. And in collaboration with Molecular Foundry users, they have demonstrated lipitoids’ effectiveness in the delivery of DNA and RNA to a wide variety of cell lines.
Today, researchers studying lipitoids for potential therapeutic applications have shown that these materials are nontoxic to the body and can deliver nucleotides by encapsulating them in tiny nanoparticles just one billionth of a meter wide – the size of a virus.
Now Qi hopes to add his CRISPR-based COVID-19 therapy to the Molecular Foundry’s growing body of lipitoid delivery systems.
In late April, the Stanford researchers tested a type of lipitoid – Lipitoid 1 – that self-assembles with DNA and RNA into PAC-MAN carriers in a sample of human epithelial lung cells.
According to Qi, the lipitoids performed very well. When packaged with coronavirus-targeting PAC-MAN, the system reduced the amount of synthetic SARS-CoV-2 in solution by more than 90%. “Berkeley Lab’s Molecular Foundry has provided us with a molecular treasure that transformed our research,” he said.
The team next plans to test the PAC-MAN/lipitoid system in an animal model against a live SARS-CoV-2 virus. They will be joined by collaborators at New York University and Karolinska Institute in Stockholm, Sweden.
If successful, they hope to continue working with Connolly and his team to further develop PAC-MAN/lipitoid therapies for SARS-CoV-2 and other coronaviruses, and to explore scaling up their experiments for preclinical tests.
“An effective lipitoid delivery, coupled with CRISPR targeting, could enable a very powerful strategy for fighting viral disease not only against COVID-19 but possibly against newly viral strains with pandemic potential,” said Connolly.
“Everyone has been working around the clock trying to come up with new solutions,” added Qi, whose preprint paper was recently peer-reviewed and published in the journal Cell. “It’s very rewarding to combine expertise and test new ideas across institutions in these difficult times.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- COVID-19 Breakthrough: Scientists Discover How the SARS-CoV-2 Virus Evades Our Immune System
A discovery by researchers at the Texas A&M College of Medicine could lead to new therapies to prevent the virus from proliferating in the human body. The immune system is a complex network of cells ...
- FluroTest Provides System Development Update; Announces Further Progress Optimizing the Immunoassay for SARS-CoV-2 Detection
TD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a developer of diagnostics technology in high output rapid antigen testing for ...
- COVID Breakthrough: New Potent Antiviral Against SARS-CoV-2, RSV and Other Respiratory RNA Viruses
Center for Translational Antiviral Research Reports Novel Drug Class with Activity Against SARS-CoV-2 The COVID-19 pandemic and resurgence of infections by other respiratory RNA viruses such as respir ...
- Rice University: Omicron mutations may help SARS-CoV-2 evade antibodies
Scientists working on a Centers for Disease Control and Prevention-funded project led by Rice University have compiled a list of mutations in the SARS-CoV-2 spike protein that may make the omicron ...
- 'Immune imprinting' by different SARS-CoV-2 spike sequences from variants, vaccines means we now have diverse patterns
New research shows that the first SARS-CoV-2 spike protein a person encounters, be it by vaccination or infection, shapes their subsequent immune response against current and future variants. That is, ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- COVID-19 UPDATES: 651 new Idaho COVID-19 cases, 6 new deaths
Idaho officials reported 651 new COVID-19 cases and 6 new deaths Wednesday. That brings the total confirmed and probable cases reported since March 2020 to 310,661. There are a total of 246,356 ...
- FDA clears AstraZeneca’s COVID-19 antibody treatment for immunocompromised
The Food and Drug Administration authorized the first injectable monoclonal antibody cocktail for long-term prevention of COVID-19 among people with weakened ...
- Massachusetts coronavirus cases surge 5,403, the most daily cases since January
State health officials on Wednesday reported the most daily cases since mid-January, while COVID-19 hospitalizations jumped for the 13th straight day.
- Kentucky Congressman Brett Guthrie tests positive for COVID-19 in breakthrough case
Congressman Brett Guthrie, R-2nd District, said he has tested positive for COVID-19. Guthrie said on social media he is "fully vaccinated." ...
- 5,403 new COVID-19 cases, 12 additional deaths reported in Massachusetts
The Massachusetts Department of Public Health has released the latest COVID-19 vaccine and case numbers for the state.